RxDoctor Payments Data

Alicia Thomas

Family · Springfield, MONPI 1154787638

Payments from drug & device makers

$7,251in general payments, 2019–2025

Across 309 payments — averaging $23.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AbbVie$810
  • Otsuka America Pharmaceutical, Inc.$637
  • Lilly USA, LLC$528
  • Axsome Therapeutics, Inc.$438
  • GSK$311
  • plus $3K from 34 others

What the payments were for

  • Travel & lodging$97313%
  • Food & beverage$6,20085%
  • Education$781%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,251 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.

See all family providers in Missouri

Medicare billing

Part B allowed, 2024
$85,238
Medicare patients
25
Services billed
1,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl394$779,833
OzempicSemaglutide66$70,142
Breztri AerosphereBudesonide/Glycopyr/Formoterol61$48,895
FarxigaDapagliflozin Propanediol54$42,091
VraylarCariprazine Hcl27$38,047
MounjaroTirzepatide23$26,010
RexultiBrexpiprazole13$19,120
CaplytaLumateperone Tosylate11$18,185
TrulicityDulaglutide12$12,489
EntrestoSacubitril/Valsartan17$11,543
DayvigoLemborexant34$10,916
Buprenorphine Hcl94$9,209
TrintellixVortioxetine Hydrobromide13$6,975
LinzessLinaclotide11$5,635
Pregabalin62$2,202

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$2,018$779,833394 claims
AstraZenecaBreztri Aerosphere, Farxiga$139$90,985115 claims
Novo NordiskOzempic$87$70,14266 claims
AbbVieVraylar, Linzess$810$43,68238 claims
Lilly USA, LLCMounjaro, Trulicity$528$38,49835 claims
Otsuka America Pharmaceutical, Inc.Rexulti$637$19,12013 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$113$18,18511 claims
NovartisEntresto$70$11,54317 claims
Eisai Inc.Dayvigo$17$10,91634 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$29$6,97513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.

Other family in Springfield

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →